Platelet Transfusion for Treatment of Patent Ductus Arteriosus in ThrombocytopenicPreterm Neonates
- Conditions
- Health Condition 1: null- Neonates with gestational age less than 35 weeks with hemodynamically significant PDA
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 44
1)Gestational age less than 35 weeks
2)PDA detected for the first time at less than 14 days of postnatal age
3)Clinically and/or echocardiographically hemodynamically significant PDA
Note: ELBW neonates will be screened in first 48 hours as per unit policy; the rest will undergo echocardiography only when there are clinical signs of PDA.
4)Platelet count within 24 hours prior to inclusion is less than 100,000 per microliter.
Note: If a platelet count is already available within 24 hours prior to inclusion it will be accepted as a valid platelet count. If not, an urgent absolute platelet count will be performed.
Echocardiographically proven structural congenital heart disease.
2) Major life-threatening malformation
3) Received platelet concentrate between the last available platelet count and the point of randomisation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome variable will be time to closure of PDA post randomizationTimepoint: The primary outcome variable will be time to closure of PDA post randomization within a 5 day period
- Secondary Outcome Measures
Name Time Method